{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:06:27Z","timestamp":1788444387047,"version":"build-2803163510"},"reference-count":43,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>Vaginal rings address a critical need for an independently initiated, long-acting HIV prevention method, but their design must be acceptable to promote uptake and adherence. Human-centered design (HCD) may help address design preference questions. In two Phase I studies of vaginal rings for HIV prevention conducted in the United States, we used qualitative interviews to assess participants' perceptions and opinions of the physical characteristics of the ring they used and of a ring's physical characteristics after comparing four ring designs presented via a visual tool. Users were found to prefer ring designs that appear easy to use, are physically comfortable, that function well, and are aesthetically pleasing. The parameters for these features varied widely. Product developers and marketers should consider marketing messages in which the target users feel this product is made to meet their needs and desires. Product developers are encouraged to design using HCD early in ring development (Clinical Trial Registration number: NCT03234400 and NCT03670355).<\/jats:p>","DOI":"10.1089\/aid.2021.0077","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:18:29Z","timestamp":1640909909000},"page":"313-326","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Users' Preferred Characteristics of Vaginal Rings for HIV Prevention: A Qualitative Analysis of Two Phase I Trials"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-5976","authenticated-orcid":false,"given":"Imogen","family":"Hawley","sequence":"first","affiliation":[{"name":"Global Public Health Impact Center, RTI International, Berkeley, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Song","sequence":"additional","affiliation":[{"name":"Magee-Womens Research Institute, Microbicide Trials Network, Pittsburgh, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Scheckter","sequence":"additional","affiliation":[{"name":"Family Health International 360, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"McClure","sequence":"additional","affiliation":[{"name":"Family Health International 360, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna","family":"Piper","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Disease, DAIDS, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice A.","family":"Chen","sequence":"additional","affiliation":[{"name":"University of Pittsburgh\/Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Hoesley","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Y.","family":"Liu","sequence":"additional","affiliation":[{"name":"Bridge HIV at the San Francisco Department of Public Health, San Francisco, California, USA."},{"name":"Department of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"van der Straten","sequence":"additional","affiliation":[{"name":"Department of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco, San Francisco, California, USA."},{"name":"ASTRA Consulting, Kensington, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"e_1_3_7_2_2","unstructured":"UNAIDS: Global HIV & AIDS statistics 2020 fact sheet. Available at https:\/\/www.unaids.org\/en\/resources\/fact-sheet (2019) accessed November20 2020."},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3463-4"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000801"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224898"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02949-4"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002028"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145642"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2015.08.007"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02457-0"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/02681102.2019.1667289"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1524500418761624"},{"key":"e_1_3_7_13_2","volume-title":"Proceedings of the International Conference on Advanced Visual Interfaces","author":"Wang Y","unstructured":"Wang Y, , Masoodian M: Designing visual tools to facilitate human-centered design. Proceedings of the International Conference on Advanced Visual Interfaces. Salerno, Italy: Association for Computing Machinery, 2020:Article 81."},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1049732318786485"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/10837450.2017.1339085"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3180415ded"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.09.029"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.09.008"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0275"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197269"},{"key":"e_1_3_7_21_2","unstructured":"Clinicaltrials.gov. A phase 1 randomized pharmacokinetics and safety study of extended duration dapivirine vaginal rings. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03234400 (2019) accessed November9 2020."},{"key":"e_1_3_7_22_2","unstructured":"Clinicaltrials.gov. Pharmacokinetic and safety study of a 90 day intravaginal ring containing tenofovir. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03670355 (2019) accessed November9 2020."},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e3283590632"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01431-12"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199778"},{"key":"e_1_3_7_26_2","unstructured":"Roberts ST Hawley I Luecke EH et al.: Acceptability and preference for 3-month versus 1-month vaginal rings for HIV-1 risk reduction among participants in a phase 1 trial. Paper presented at: AIDS 2020 Virtual: 23rd International AIDS Conference 2020."},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25747"},{"key":"e_1_3_7_28_2","unstructured":"Stoner MCD BE Gundacker HM Hawley I et al.: Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring. Plos One. Under Review."},{"key":"e_1_3_7_29_2","unstructured":"MTNstopshiv.org. MTN-036\/IPM 047 Study Implementation Materials. Available at https:\/\/mtnstopshiv.org\/research\/studies\/mtn-036ipm-047\/mtn-036ipm-047-study-implementation-materials accessed August21 2021."},{"key":"e_1_3_7_30_2","unstructured":"MTNstopshiv.org. MTN-038 Study Implementation Materials. Available at https:\/\/mtnstopshiv.org\/research\/studies\/mtn-038\/mtn-038-study-implementation-materials accessed August21 2021."},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002655"},{"key":"e_1_3_7_32_2","doi-asserted-by":"crossref","unstructured":"Bischof N Comi A Eppler MJ: Knowledge visualization in qualitative methods\u2014Or How Can I See What I Say? Paper presented at: 2011 15th International Conference on Information Visualisation 2011.","DOI":"10.1109\/IV.2011.14"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.01.026"},{"key":"e_1_3_7_34_2","volume-title":"Diffusion of innovations,","author":"Rogers E","year":"2003","unstructured":"Rogers E: Diffusion of innovations, 5th ed. New York, NY: Simon and Schuster, 2003."},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/15710882.2011.563314"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001452"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02576-8"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.12688\/gatesopenres.13182.1"},{"key":"e_1_3_7_39_2","first-page":"62","article-title":"State of the art in intravaginal ring technology for topical prophylaxis of HIV infection","volume":"14","author":"Kiser PF","year":"2012","unstructured":"Kiser PF, , Johnson TJ, , Clark JT: State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev, 2012; 14:62\u201377.","journal-title":"AIDS Rev"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-013-0235-5"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25170"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.2196\/10474"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/2325958219841366"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25536"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2021.0077","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2021.0077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2021.0077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:16:23Z","timestamp":1777367783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2021.0077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1089\/aid.2021.0077"],"URL":"https:\/\/doi.org\/10.1089\/aid.2021.0077","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}